Des Arc Nursing And Rehabilitation Center | |
2216 West Main Street, Des Arc, Arkansas 72040 | |
(870) 256-4194 | |
Name | Des Arc Nursing And Rehabilitation Center |
---|---|
Location | 2216 West Main Street, Des Arc, Arkansas |
Certified By | Medicare and Medicaid |
No. of Certified Beds | 98 |
Occupancy Rate | 53.88% |
Medicare ID (CCN) | 045236 |
Legal Business Name | Prairie Snf Operations Llc |
Ownership Type | For Profit - Corporation |
NPI Number | 1114915782 |
Organization Name | DIVERSICARE LEASING CORP. |
Doing Business As | DES ARC NURSING & REHABILITATION CENTER |
Address | 2216 Main St, Des Arc, AR 72040 |
Phone Number | 870-256-4194 |
News Archive
Golimumab, a new tumour necrosis factor-α (TNF-α) inhibitor reduces the signs and symptoms of rheumatoid arthritis in patients who have previously received any other TNF-α inhibitor, and might be a good option for patients who have inadequate responses to one or two other TNF-α inhibitors, finds an Article published Online first and in this week's edition of The Lancet.
Reovirus, which commonly infects humans without causing any symptoms, may trigger an immune response to gluten that causes celiac disease, report US researchers.
UCLA researchers pinpointed a new mechanism that potently activates T-cells, the group of white blood cells that play a major role in fighting infections.
The Lewy Body Dementia Association, announced today that UC San Diego Health has been named a LBDA Research Centers of Excellence, a partnership of 24 pre-eminent academic medical research centers across the United States. LBDA is a leading advocacy group dedicated to raising awareness and advancing research and treatment of Lewy body dementia.
› Verified 6 days ago
NPI Number | 1164806824 |
Organization Name | PRAIRIE SNF OPERATIONS LLC |
Address | 2216 Main St, Des Arc, AR 72040 |
Phone Number | 870-256-4194 |
News Archive
Golimumab, a new tumour necrosis factor-α (TNF-α) inhibitor reduces the signs and symptoms of rheumatoid arthritis in patients who have previously received any other TNF-α inhibitor, and might be a good option for patients who have inadequate responses to one or two other TNF-α inhibitors, finds an Article published Online first and in this week's edition of The Lancet.
Reovirus, which commonly infects humans without causing any symptoms, may trigger an immune response to gluten that causes celiac disease, report US researchers.
UCLA researchers pinpointed a new mechanism that potently activates T-cells, the group of white blood cells that play a major role in fighting infections.
The Lewy Body Dementia Association, announced today that UC San Diego Health has been named a LBDA Research Centers of Excellence, a partnership of 24 pre-eminent academic medical research centers across the United States. LBDA is a leading advocacy group dedicated to raising awareness and advancing research and treatment of Lewy body dementia.
› Verified 6 days ago
NPI Number | 1306279708 |
Organization Name | PRAIRIE OPERATIONS, LLC |
Doing Business As | DES ARC NURSING AND REHAB CENTER |
Address | 2216 West Main Street, Des Arc, AR 72040 |
Phone Number | 870-256-4194 |
News Archive
Golimumab, a new tumour necrosis factor-α (TNF-α) inhibitor reduces the signs and symptoms of rheumatoid arthritis in patients who have previously received any other TNF-α inhibitor, and might be a good option for patients who have inadequate responses to one or two other TNF-α inhibitors, finds an Article published Online first and in this week's edition of The Lancet.
Reovirus, which commonly infects humans without causing any symptoms, may trigger an immune response to gluten that causes celiac disease, report US researchers.
UCLA researchers pinpointed a new mechanism that potently activates T-cells, the group of white blood cells that play a major role in fighting infections.
The Lewy Body Dementia Association, announced today that UC San Diego Health has been named a LBDA Research Centers of Excellence, a partnership of 24 pre-eminent academic medical research centers across the United States. LBDA is a leading advocacy group dedicated to raising awareness and advancing research and treatment of Lewy body dementia.
› Verified 6 days ago
Ratings from Surveys (Inspections): | |
Ratings from Quality Measures: | |
Ratings from Staffing Data: | |
Overall Rating: |
---|
News Archive
Golimumab, a new tumour necrosis factor-α (TNF-α) inhibitor reduces the signs and symptoms of rheumatoid arthritis in patients who have previously received any other TNF-α inhibitor, and might be a good option for patients who have inadequate responses to one or two other TNF-α inhibitors, finds an Article published Online first and in this week's edition of The Lancet.
Reovirus, which commonly infects humans without causing any symptoms, may trigger an immune response to gluten that causes celiac disease, report US researchers.
UCLA researchers pinpointed a new mechanism that potently activates T-cells, the group of white blood cells that play a major role in fighting infections.
The Lewy Body Dementia Association, announced today that UC San Diego Health has been named a LBDA Research Centers of Excellence, a partnership of 24 pre-eminent academic medical research centers across the United States. LBDA is a leading advocacy group dedicated to raising awareness and advancing research and treatment of Lewy body dementia.
› Verified 6 days ago
Number of Facility Reported Incidents | 0 |
Number of Substantiated Complaints | 0 |
Number of Fines | 0 |
Total Amount of Fines in Dollars | $0 |
Number of Payment Denials | 0 |
Total Number of Penalties | 0 |
Experience Measure | Provider | National Avg. |
---|---|---|
Percentage of long-stay residents whose need for help with daily activities has increased | 24.86 | 14.46 |
Percentage of long-stay residents who lose too much weight | 1.32 | 5.51 |
Percentage of low risk long-stay residents who lose control of their bowels or bladder | 58.49 | 48.41 |
Percentage of long-stay residents with a catheter inserted and left in their bladder | 0 | 1.79 |
Percentage of long-stay residents with a urinary tract infection | 0 | 2.65 |
Percentage of long-stay residents who have depressive symptoms | 1.01 | 5.05 |
Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
Percentage of long-stay residents experiencing one or more falls with major injury | 4.23 | 3.36 |
Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 92.96 | 93.87 |
Percentage of long-stay residents who received an antipsychotic medication | 7.77 | 14.2 |
Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 88.76 | 83.88 |
Percentage of short-stay residents who newly received an antipsychotic medication | 8.11 | 1.79 |
Percentage of long-stay residents whose ability to move independently worsened | 25.76 | 17.09 |
Percentage of long-stay residents who received an antianxiety or hypnotic medication | 17.02 | 19.7 |
Percentage of high risk long-stay residents with pressure ulcers | 15.04 | 7.32 |
Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 95.52 | 95.98 |